Researchers from the AMP RA/Lupus Network came together in June at the annual FOCIS meeting to share their progress as they perform a systematic molecular deconstruction of human diseases…
Lupus Incidence, Prevalence Differ by Race
NEW YORK (Reuters Health)—Racial and ethnic disparities in systemic lupus erythematosus (SLE) incidence and prevalence are considerable, according to two new studies of data from California and Manhattan. “The most important finding of the population-based California and New York registries is the confirmation of the racial and ethnic disparities of SLE, with the highest incidence…
Care Fragmentation May Increase Risk of SLE Damage & Disease Severity
Despite the wide spread adoption of electronic health records, many systems are unable to exchange data, creating the potential for fragmented care. New research examined the effect of care fragmentation on patients with SLE in the Chicago HealthLNK Data Repository, finding that care fragmentation plays an independent role in an increased frequency of infection and disease-related morbidity damage. Researchers also found a relationship between care fragmentation, race and public insurance…
New SLE Criteria Under Development: A Joint Effort of the ACR & EULAR
MADRID—Systemic lupus erythematosus (SLE) experts in North America and Europe are working together to refine the classification system for the disease, with the goal of producing a new set of criteria that is simpler to use and more scientifically rigorous than any classification approach previously published, speakers involved with the process said at the 2017…
Comorbidities & Risk Factors for Developing SLE
MADRID—Researchers have found that systemic lupus erythematosus (SLE) is independently linked with bipolar disorder and say the findings point to a need for greater awareness of psychiatric problems in patients with SLE. In work led by investigators at Tel Aviv University in Israel and presented at the 2017 Annual European Congress on Rheumatology (EULAR), researchers…
Rituximab May Help Pediatric Patients with SLE
Although rituximab is not indicated for adults with SLE, a recent review suggests that it may be safe and effective for treating pediatric SLE. The review found that rituximab improved renal function and reduced proteinuria in pediatric patients. It may also prevent relapse and improve disease activity…
ARHP Clinical Focus Course Targets Management of Adults with SLE
This year the ARHP Clinical Focus Course brings together experts in the field to provide an interprofessional approach to the management of systematic lupus erythematosus (SLE) to improve patient outcomes. The daylong course, titled Systemic Lupus Erythematosus: Taming the Wolf—Salient Lessons from Practice and Research, which is offered on Nov. 4, will provide a case-based…
Dr. Peter Schur Discusses Lupus Treatment, Management Advances in Past 50 Years
Although systemic lupus erythematosus still does not have a definite cause or cure, rheumatologists and researchers over the past 50 years have witnessed and contributed to a great deal of progress that helps patients, says Peter H. Schur, MD, director emeritus of the Lupus Center, Brigham and Women’s Hospital, and professor, Harvard Medical School, Boston. Dr. Schur’s…
Infection Rates for Patients with SLE on Immunosuppressive Drugs
A comparison study of the serious infection burden among patients with lupus found no major differences in patients treated with three separate immunosuppressive drug regimens. Given that serious infections are among the leading causes of hospitalizations and death in patients with systemic lupus erythematosus (SLE), researchers investigated whether the incident rates differed in patients who…
Voclosporin Promising for Lupus Nephritis
In a recent clinical trial, voclosporin proved safe and effective at both low and high doses as a treatment for lupus nephritis…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 45
- Next Page »